Introduction
It is estimated that 1.6 million new cases of cancer will be diagnosed, leading to over a half a million death from cancer or about 1,600 people per day, accounting for 1 out of 4 deaths in the US [1] . Major advances in genetic testing of solid tumor biopsies have fundamentally changes how cancers are targeted and treated which ultimately leads to the improved survival rates. However, solid tumor sampling is invasive, sometimes unavailable, impractical for longitudinal monitoring, heterogeneous, or unable to obtain sufficient tumor content; thus, tissue biopsy sampling is a major challenge in the treatment and management of cancers [2] . Blood biopsy, particularly circulating cell-free DNA (cfDNA), is emerging as a non-invasive method for cancer targeted therapy by identification of specific druggable genetic alterations in bloodstream [3] . Table 1 showed side-by-side comparison between blood biopsy and tissue biopsy. Advanced technology to isolate, quantify and analyze cfDNA has led to the identification of cancer-specific aberrations in circulation such as chromosomal abnormalities, gene mutations, methylation and copy number variations which share identical characteristics of tumor tissues [4, 5] . The clinical utility of cfDNA in the personalized management of cancer will serve as a major game changer with the overarching goal to optimize overall cancer survival rates.
History of circulating cell-free DNA
Most of the nucleic acids (DNA and RNA) in the body are located within cells, but a fair amount of extracellular nucleic acids can also be found circulating in the bloodstream. Since the first discovery of cfDNA in 1948 by Mandel and Metais in the blood, researchers have found that cfDNA track and discriminate cancer patients and healthy individuals in two folds: first by its elevated concentration and second, by the presence of tumor-specific alterations [6] . Tumor-specific cfDNA has been found in a wide range of cancers, as listed by not limited: hematological, colorectal, pancreatic, skin, head-and-neck, lung, breast, gastric, prostate, and cervix [4] [5] [6] . This suggests that cfDNA is a hallmark for all cancer and may reflect a pathological process that can be used to diagnose cancer, to monitor disease progression, and to identify treatment responses. Evidence existed in terms of the origin of these cell-free circulating genetic molecules: [1] they are shed into bloodstream through "active" release of newly synthesized nucleic acids; or [2] they are the "passive" endproducts of necrotic and/or apoptotic cell death [7, 8] .
Extraction of circulating cell-free DNA
Currently, although a number of methods for extraction of cfDNA are employed, the efficiency and yield are still low due to loss of starting materials during extraction, and its quantification is variable because of lack of standardization [9, 10] . Nevertheless, for healthy subjects, the average concentration of circulating cfDNA is found to be 10-30 ng/mL with values of cancer patients exceeding 100 ng/mL of plasma [11] [12] [13] . The estimation of cfDNA contributed by tumors using multiple methods is between 0.01 to 90% [12] . Most cfDNA fragments measured between 150 to 200 base pairs in length, with a variable half-life in the circulation ranging from 15 minutes to several hours [13] . The amount of cfDNA is influenced by tumor progression, turnover of tumor, tumor size, as well as clearance, degradation, and filtering by the blood and lymphatic circulation [13] . The most common published extraction methods for cfDNA are the commercially available spin column extraction kits. Other reported methods of extraction include magnetic beads, phenol/ chloroform extraction, and alkaline salting. The efficiency of cfDNA extraction can directly impact the outcome of mutation detection i.e., assay sensitivity ( Table 2) . 
Utility of circulating cell-free DNA in cancer
Circulating cfDNA-based non-invasive method can be used to detect and monitor specific and predictive biomarkers that are recommended for the proper treatment of cancer patients according to the molecular characterization of the specific cancer. For example by using qPCR, digital PCR or sequencing, KRAS and EFGR mutation status can be obtained from cfDNA in cancer patients before, during and after targeted therapy [14] . The whole exome sequencing of cfDNA by next generation sequencing (NGS) can provide a global, complete and real-time picture regarding molecular status of tumor progression [15] . Most importantly, tumor load could be quantitatively estimated from ultra-deep cfDNA mutation profiling [16] . Methylation status present in the tumor genome can also be detected in the cfDNA fragments [17] . Overall, the development of patientcentered molecular diagnostics with blood biopsy makes perfect sense, and it's promising and beneficial to patient healthcare. Table 2 summarized advanced technologies currently deployed for circulating cell-free DNA in oncology.
Challenges and future perspectives
Current cancer management for treating cancer patients with precision therapy is still challenged by the following limitations:
Tumor heterogeneity: Tumors are heterogeneous and continuously polyclonal expansion, complicating diagnosis, treatment and the assessment of acquired resistance. Furthermore, tumor tissues are limited both spatially to the region biopsied, and temporally to the state of tumor at the time of biopsy [18] . solution for precision cancer management (Table1). Clinical tests employing cfDNA are inherently specific, sensitive, and are able to capture both intra-and inter-tumor heterogeneity in real time [16, 19] .
Overcome the limitations of blood biopsy: Circulating cfDNA is highly fragmented and presented at very low concentrations; therefore, its isolation is challenging because of the requirement of large volume input, costs, and labor-intensity. Current cfDNA recovery efficiency using the standard silica membrane/bead method is extremely low, due to the unavoidable loss in steps such as binding, washing and elution. Accordingly, it is imperative to develop novel methodologies that enable "full-recovery" of both necrotic and apoptotic cell death-associated cfDNA for the accurate quantification as well as the detection of the specific mutation(s) in the same sample, consequently, the improvement of analytical sensitivity and specificity.
New high-sensitivity technology: Detection of low-frequency mutations through periodic "blood biopsy" analysis could monitor tumor progression before the lesions are large enough to be detected by imaging [3] . Analysis beyond a single mutation could also be warranted to capture tumor heterogeneity for effective treatment decision-making [20] . Blood biopsies are not as spatially limited as tissue biopsies, and can display a global spectrum of mutations that occur throughout cancer development in our body. Nevertheless, the sensitivity of conventional analytical methods such as Sanger sequencing is not sufficient to detect low frequency variants. In this respect, advanced NGS technology could provide a cost-effective alternative for high-throughput analysis of multiple mutations with high sensitivity. In addition, PCR-based new platforms with the features of single-molecular amplification and/or selective enrichment of tumor-specific cfDNA from a dominantly normal population, have demonstrated unprecedented assay sensitivity [21, 22] .
Larger clinical study:
Although promising proof-of-concept data in small cohorts of cancer patients from various studies have been reported, larger prospective trials are needed to confirm cfDNA clinical utility. Future studies need to demonstrate whether cfDNA-derived mutation profile in blood can contribute to an improved treatment outcome of cancer patients.
Conclusion
Blood biopsy employing cfDNA can identify multiple mutant tumor genes circulating in our bloodstream at multiple time points instead of using invasive limited-time-only tissue biopsy. Blood biopsy is expected to provide clinicians with faster, cheaper, broader, less invasive ways to assess cancer patients' clinical status and response to therapy. Blood biopsy-based tests for multiple mutation profiles via NGS could become a gold standard of new-generation cancer management in the era of precision medicine.
